ADMA analyst estimates
ADMA Biologics (ADMA) analyst ratings, the average price target and its range, and every firm's latest call.
ADMA analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Jul 15, 2026 | Mizuho Securities | Adma Biologics price target lowered to $17 from $20 at Mizuho | $17.00 |
| Jun 10, 2026 | Raymond James | Adma Biologics resumed with an Outperform at Raymond James | $21.00 |
| May 7, 2026 | Canaccord Genuity | Adma Biologics price target lowered to $18 from $21 at Canaccord | $18.00 |
| Apr 20, 2026 | Canaccord Genuity | Adma Biologics initiated with a Buy at Canaccord | $21.00 |
| Apr 13, 2026 | Mizuho Securities | Adma Biologics price target lowered to $24 from $30 at Mizuho | $24.00 |
| Oct 14, 2024 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on ADMA Biologics (ADMA) | $18.00 |
| Jun 20, 2024 | Mizuho Securities | ADMA Biologics (ADMA) PT Raised to $14 at Mizuho | $14.00 |
| Jan 3, 2023 | H.C. Wainwright | HC Wainwright & Co. Maintains Buy on ADMA Biologics, Raises Price Target to $4.5 | $4.50 |
| Nov 10, 2022 | Mizuho Securities | Mizuho Maintains Buy on ADMA Biologics, Raises Price Target to $6 | $6.00 |
| Jul 25, 2022 | H.C. Wainwright | HC Wainwright & Co. Maintains Buy on ADMA Biologics, Lowers Price Target to $4 | $4.00 |
- 3 firms rate ADMA: 2 buy, 1 hold, 0 sell.
- The average price target is $18.67 from 3 analysts, from $17.00 to $21.00.
Updated 2026-11-03 00:00 UTC